<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521063</url>
  </required_header>
  <id_info>
    <org_study_id>86-17</org_study_id>
    <nct_id>NCT03521063</nct_id>
  </id_info>
  <brief_title>Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.</brief_title>
  <official_title>Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Autonoma de San Luis Potosí</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of budesonide to poractant alfa to prevent bronchopulmonary
      dysplasia in preterm infants with respiratory distress syndrome. Half of the participants
      will receive budesonide and poractant alfa in combination, and the other half will receive
      poractant alfa with saline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized double bind controlled trial, designed to evaluate the addition of budesonide to
      poractant alfa to prevent bronchopulmonary dysplasia (BPD) in preterm infants with
      respiratory distress syndrome (RDS).

      The usual treatment of RDS includes ventilatory support and exogenous surfactant, however, a
      cronic lung disease known as BPD, is a complication found in many of these patients.

      BPD is a complex disease occurring in preterm infants recovering from RDS and inflammation
      plays a key role in its physiopathology.

      Animal derived surfactants have demonstrated to decrease the incidence of BPD, and porcine
      surfactant (poractant alfa) has and increased effect compared with bovine surfactant
      (beractant).

      Budesonide is an inhaled anti-inflammatory steroid that has shown to reduce BPD when combined
      with beractant by decreasing lung inflammation, without secondary systemic effects, when
      combined with poractant alfa it could enhance even more this anti-inflammatory effect.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchopulmonary dysplasia or death</measure>
    <time_frame>Oxygen requirement at 36 weeks post menstrual age in patients &lt;32 weeks. Oxygen requirement between 29 to 55 days of age in patients &gt;32 weeks</time_frame>
    <description>Diagnosis of bronchopulmonary dysplasia according to NICHD criteria</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <condition>Infant,Premature</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Poractant alfa/budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A mixture of poractant (200mg/kg) and budesonide (0.25 mg/kg) will be instilled intratracheal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poractant alfa/saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A mixture of poractant (200mg/kg) and saline (1 ml/kg) will be instilled intratracheal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Drug: Budesonide inhalation suspension</description>
    <arm_group_label>Poractant alfa/budesonide</arm_group_label>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poractant Alfa</intervention_name>
    <description>Drug: Poractant alfa intratracheal suspension</description>
    <arm_group_label>Poractant alfa/budesonide</arm_group_label>
    <arm_group_label>Poractant alfa/saline</arm_group_label>
    <other_name>Curosurf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Sodium chloride injection 0.9%</description>
    <arm_group_label>Poractant alfa/saline</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birth weight &lt;1500g

          -  Gestational age ≥ 26 weeks

          -  Respiratory distress syndrome that requires exogenous surfactant at birth or in the
             first 12 hours of life.

        Exclusion Criteria:

          -  Major congenital anomalies.

          -  Perinatal asphyxia

          -  Respiratory depression secondary to general anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RAUL H ROQUE SANCHEZ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RAUL H ROQUE SANCHEZ, MD</last_name>
    <phone>+524448342701</phone>
    <phone_ext>1522</phone_ext>
    <email>raul_roque@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FRANCISCO J ESCALANTE PADRON, MD</last_name>
    <phone>+524448342746</phone>
    <email>fcoescalantep@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Central Dr. Ignacio Morones Prieto</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78290</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RAUL H ROQUE SANCHEZ, MD</last_name>
      <phone>+524448342701</phone>
      <phone_ext>1522</phone_ext>
      <email>raul_roque@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>FRANCISCO J ESCALANTE PADRON, MD, MSC</last_name>
      <phone>+524448342746</phone>
      <email>fcoescalantep@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>RAUL H ROQUE SANCHEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>FRANCISCO J ESCALANTE PADRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9.</citation>
    <PMID>11401896</PMID>
  </reference>
  <reference>
    <citation>Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Halliday HL; European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update. Neonatology. 2013;103(4):353-68. doi: 10.1159/000349928. Epub 2013 May 31.</citation>
    <PMID>23736015</PMID>
  </reference>
  <reference>
    <citation>Singh N, Halliday HL, Stevens TP, Suresh G, Soll R, Rojas-Reyes MX. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2015 Dec 21;(12):CD010249. doi: 10.1002/14651858.CD010249.pub2. Review.</citation>
    <PMID>26690260</PMID>
  </reference>
  <reference>
    <citation>Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, Tsai CH, Lin HC. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2016 Jan 1;193(1):86-95. doi: 10.1164/rccm.201505-0861OC.</citation>
    <PMID>26351971</PMID>
  </reference>
  <reference>
    <citation>Venkataraman R, Kamaluddeen M, Hasan SU, Robertson HL, Lodha A. Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis. Pediatr Pulmonol. 2017 Jul;52(7):968-975. doi: 10.1002/ppul.23680. Epub 2017 Feb 6. Review.</citation>
    <PMID>28165675</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 28, 2018</last_update_submitted>
  <last_update_submitted_qc>April 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</investigator_affiliation>
    <investigator_full_name>Raúl Héctor Roque Sánchez</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>bronchopulmonary dysplasia</keyword>
  <keyword>respiratory distress syndrome</keyword>
  <keyword>budesonide</keyword>
  <keyword>poractant alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Poractant alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

